Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

Aug 02 2013

• By Paul Bonanos

Related Content

P&G Spinout Spins Off Another Company, While Looking To Partner Mid-Stage Oral Anemia Candidate

May 21 2012

AstraZeneca Makes Good On Vow To Build CV Pipeline With AlphaCore Buy

Apr 03 2013

Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

Mar 25 2013

U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen

Apr 04 2008

Bringing New Blood to the Anemia Market

Dec 01 2009

Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate

May 10 2007

The Other Fish In The Sea: AstraZeneca Buys Omthera

May 28 2013

Related Companies

AstraZeneca PLC

FibroGen, Inc.

Astellas Pharma, Inc.

Amgen, Inc.

3SBio Inc.

MedImmune LLC

AlphaCore Pharma

Omthera Pharmaceuticals, Inc.

Akebia Therapeutics, Inc.

GSK plc

Additional Topics

Japan Asia Pacific Clinical Trials Business Strategies BioPharmaceutical

More from Japan

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window